A decade from now, considering Vertex's pipeline, the company could potentially offer a treatment for every CF patient. Today, about 5,000 people with the disease don't make any CFTR protein ...

a dual antagonist of the BAFF and APRIL cytokines that Vertex reckons could be a ‘pipeline-in-a-product’ with potential in other indications, including lupus nephritis and autoimmune cytopenias.

While Vertex’s main focus is on the development and strengthening of its CF franchise, the company also has a rapidly advancing mid- to late-stage pipeline in other disease areas beyond CF ...